Key Highlights
- Freenome shares are trading down 6.31% at $10.83 versus a prior close of $11.56.
- Third quarter Revenue was $183.5 million, driven by $180 million of Abbott license revenue.
- Net income was $60.1 million.
- Fourth quarter revenue guidance is $2 million to $4 million.
- Cash of about $430 million is expected to fund operations into 2028.
Freenome (NASDAQ:FRNM) is trading down 6.31% at $10.83 after a third quarter built on a one-time license payment. Revenue was $183.5 million versus $1 million a year ago, driven by $180 million of Abbott license revenue recognized after FDA approval of SimpleScreen CRC. Peer Guardant Health (NASDAQ:GH) is trading up 0.18%.
One-Time Payment Drives Profit
Net income was $60.1 million, or $0.58 per share. The company ended the quarter with about $430 million of cash and expects it to fund operations into 2028. Freenome has received $242.2 million of up to $885 million in Abbott payments and earns a 10% Royalty once a 20% gross Margin is reached.
Guidance Steps Down
Fourth quarter revenue guidance is $2 million to $4 million, bringing full-year revenue to $192 million to $194 million. That reflects Abbott research fees, United Kingdom service revenue and modest lab service fees, with no meaningful testing revenue or royalties expected. Management will give 2027 commercial guidance on the next call.
Launch Details
Abbott began selling SimpleScreen CRC on September 30 with an 800-person sales force, and over 2,000 clinical sites have requested collection kits. Medicare pricing is $920. UnitedHealthcare, Carelon and Cigna have added coverage, and Abbott is negotiating with most of the top 20 payers.
Management expects two larger payers to come in-network in the next couple of quarters and significant traction in 2027, with electronic medical record integrations going live in November. Abbott has trained its sales force and begun outreach to its 380,000 provider channel, and management said it is too early to give Volume guidance.
Test Improvements
The version 2 colorectal cancer test raised advanced precancerous lesion sensitivity from 13.7% to 18.2%.
Payer Adoption Decides the Next Move
The step down from $183.5 million to a $2 million to $4 million quarter is expected, so attention shifts to ordering volume. Investors will watch payer coverage wins, the electronic medical record integrations in November and any 2027 commercial guidance on the next call. Future Abbott milestone payments are the other marker.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...